Abeona Therapeutics Inc vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? Abeona Therapeutics Inc trades at $7.35 (market cap $421.19M), while ProShares Ultra Bloomberg Natural Gas ETF trades at $21.11. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | BOIL | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.45 | $87.24 |
52-Week Low | $4.17 | $18.74 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
BOIL trades at $21.085, up 1.81% in the last 24 hours, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights U.S. natural gas futures stability amid weather-driven demand shifts. The company, Beyond Oil Ltd., focuses on food-tech innovations to reduce health risks in fried foods, with recent corporate actions including a 1:2 stock split effective May 28, 2026.
The outlook for BOIL is cautious due to bearish technical trends and reliance on natural gas market volatility. Investment opportunities hinge on energy sector demand and company-specific growth in food-tech, while risks include commodity price swings and execution challenges in scaling innovations.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →